Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics, Inc. may have issued materially misleading business information to the investing public.
If you purchased ADMA Biologics, Inc. securities and would like to join the prospective action, please click “Join This Class Action.”
On March 24, 2026, Investing.com published an article entitled “ADMA Biologics shares plunge on short seller allegations.” The article stated that ADMA Biologics shares fell “after short seller Culper Research released a report alleging the company engaged in channel stuffing to inflate revenue growth.”
On this news, ADMA Biologics stock fell 16.6% on March 24, 2026.
The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.
Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.
Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.
The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.
